Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer

Gene Therapy

Volumn 7, Issue 6, 2000, Pages 481-492

  Song, K ^a   Chang, Y ^a   Prud'homme, G J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer immunotherapy; Carcinoembryonic antigen; Cytokine plasmids; Cytotoxic T lymphocytes; DNA vaccination; T helper cells

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 4; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BLOOD LEVEL; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CLONING VECTOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODY FORMATION; CARCINOEMBRYONIC ANTIGEN; COS CELLS; CYTOKINES; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS; TUMOR CELLS, CULTURED; VACCINES, DNA;

ANIMALIA;

EID: 0034103589     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301123     Document Type: Article

References (60)

1. Cohen AD, Boyer JD, Paul DB. Modulating the immune response to genetic immunization. FASEB J 1998; 12: 1611-1626.
2. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17: 131-138.
3. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996; 5: 295-302.
4. + cytotoxic T cell responses? A paradox revisited. Immunol Today 1993; 14: 344-348.
5. Engers HD et al. Functional activity in vivo of effector T cell populations. J Immunol 1984; 133: 1664-1670.
6. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol 1997; 9: 705-708.
7. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177: 249-256.
8. Bohm W et al. T cell-mediated, IFNγ-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897-908.
9. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of 1-major. Immunol 1995; 84: 173-176.
10. Boyle JS, Koniaras C, Lew AM. Influence of cellular location and expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA injection. Int Immunol 1997; 9: 1897-1906.
11. d mice that reject syngeneic tumors. J Immunol 1996; 157: 3550-3558.
12. Thompson J, Zimmermann W. The carcinoembryonic antigen gene family: structure, expression and evolution. Tumor Biol 1988; 9: 63-83.
13. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-366.
14. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43: 127-134.
15. Hunter RL, Olsen MR, Bennett B. Copolymer adjuvants and titermax. In: Stewart-Tull DES (ed). The Theory and Practical Application of Adjuvants. John Wiley: Chichester, 1995, pp 51-94.
16. Allsopp CE et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996; 25: 1137-1140.
17. Ishii KJ et al. Activity and safety of DNA plasmids encoding IL-4 and IFNgamma. Gene Therapy 1999; 6: 237-244.
18. Sin JI et al. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73: 501-509.
19. Kim JJ et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Euro J Immunol 1998; 28: 1089-1103.
20. Chow YH et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-1329.
21. Conry RM et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Therapy 1995; 2: 59-65.
22. Coffman RL, Lebman DA, Rothman P. Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993; 54: 229-270.
23. Bloom ET, Horvath JA. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity: implications for the age-related decline in CTL. J Immunol 1994; 152: 4242-4254.
24. + T cells to enhance priming for IFNγ production and diminishes IL-4 inhibition in such priming. Proc Natl Acad Sci USA 1993; 90: 10188-10192.
25. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
26. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995; 2: 96-106.
27. Schultz J et al. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum Gene Ther 1999; 10: 407-417.
28. Fagerberg J et al. Recombinant carcinoembryonic antigen and granulocyte-macrophage colony-stimulating factor for active immunization of colorectal carcinoma patients. Proceedings of the 11th Annual Meeting of the Society for Biological Therapy, Madison, WI: Society for Biological Therapy, 1996.
29. Irvine K, Kantor J, Schlom J. Comparison of a CEA-recombinant vaccinia virus, purified CEA and an anti-idiotype bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res 1993; 2: 79-94.
30. Bei R et al. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother 1994; 16: 275-282.
31. Kantor J et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Can Inst 1992; 84: 1084-1091.
32. McLaughlin JP, Schlom J, Kontor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996; 56: 2361-2367.
33. Bei R et al. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J Immunother 1998; 21: 159-169.
34. Tsuji T et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158: 4008-4013.
35. Kim JJ et al. In vivo engineering of a cellar immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
36. Michael G, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158: 1231-1237.
37. OGarra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-283.
38. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87-9: 3877-3882.
39. + T cells from αβ-TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFNγ production is IFNγ-dependent. Int Immunol 1993; 5: 1119-1128.
40. Kobayashi M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
41. Chatelain R, Varkila K, Coffman RE. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992; 148: 1182-1187.
42. + T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-1098.
43. Liew FY et al. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur J Immunol 1989; 19: 1227-1232.
44. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin-4. Annu Rev Immunol 1987; 5: 429-459.
45. Nastala CE et al. Recombinant IL-12 administration induces tumor regression in association with IFNγ production. J Immunol 1994; 153: 1697-1706.
46. Zitvogel L et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393-1403.
47. Martinotti A et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995; 25: 137-146.
48. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
49. Rakhmilevich AL et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303-1311.
50. Coor M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996; 184: 1555-1560.
51. Ulmer JB et al. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunol 1996; 89: 59-67.
52. Iwasaki A et al. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 1997; 159: 11-14.
53. Conry RM et al. Selected strategies to augment polynucleotide immunization. Gene Therapy 1996; 3: 67-74.
54. Behrens L et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998; 161: 5943-5951.
55. Erwing LP, Kluth DC, Walsh GM, Ress AJ. Initial cytokine exposure determines function of macrophages and renders them corresponsive to other cytokines. J Immunol 1998; 161: 1983-1988.
56. Sato Y et al. Immune-stimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-354.
57. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the anti-tumor effect of interleukin-4. Science 1992; 257: 548-551.
58. Chomarat P, Rybak ME, Banchereau J. Interkeukin-4. In: Thomson A (ed). The Cytokine Handbook. Academic Press: San Diego, 1998, pp 133-174.
59. I. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 1995; 2: 129-135.
60. Hartikka J et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7: 1205-1217.